Treatment with Recombinant Interferon-α2a for Patients with Chronic Hepatitis C: Predictive Factors for Biochemical and Virologic Response

References

• Kuo G, Choo Q L, Alter H J, Gitnick G L, Redeker A G, Purcell R H, et al. An assay for circulating antibodies to a major etiologic virus of human non‐A, non‐B hepatitis. Science 1989; 244: 362–4
   PubMed Web of Science ®Google Scholar
• Alter H J, Purcell R H, Shih J W, Melpolder J C, Houghton M, Choo Q L, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non‐A, non‐B hepatitis. N Engl J Med 1989; 321: 1494–500
   PubMed Web of Science ®Google Scholar
• Hopf U, Moller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke‐Handjery A, et al. Long‐term follow‐up of posttransfusion and sporadic chronic hepatitis non‐A, non‐B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10: 69–76
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Hayashi N, Mita E, Hiramatsu N, Ueda K, Takehara T, et al. Detection of hepatitis C virus RNA in chronic non‐A, non‐B liver disease. Gastroenterology 1992; 102: 692–4
   PubMed Web of Science ®Google Scholar
• Davis G L, Balart L A, Schiff E R, Lindsay K, Bodenheimer H C, Perrillo R P, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–6
   PubMed Web of Science ®Google Scholar
• Di Bisceglie A M, Martin P, Kassianides C, Lisker‐Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double‐blind, placebo‐controlled trial. N Engl J Med 1989; 321: 1506–10
   PubMed Web of Science ®Google Scholar
• Saez‐Royuela F, Porres J C, Moreno A, Castilio I, Martinez G, Galiana F, et al. High doses of recombinant α‐interferon or γ‐interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991; 113: 327–31
   Google Scholar
• Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa‐resistant chronic hepatitis C. Gastroenterology 1994; 107: 812–7
   PubMed Web of Science ®Google Scholar
• Shindo M, Di Bisceglie A M, Cheung L, Shih J WK, Cristiano K, Feinstone S M, et al. Decrease in serum hepatitis C viral RNA during alpha‐interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700–4
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon‐α. Hepatology 1992; 15: 37–41
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877–83
   PubMed Web of Science ®Google Scholar
• Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977–82
   PubMed Web of Science ®Google Scholar
• Lau J YN, Davis G L, Kniffen J, Qian K ‐P, Urdea M S, Chan C S, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501–4
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293–9
   PubMed Web of Science ®Google Scholar
• Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa‐2b and placebo in patients with chronic non‐A, non‐B hepatitis. Gastroenterology 1991; 101: 497–502
   PubMed Web of Science ®Google Scholar
• Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619–24
   PubMed Web of Science ®Google Scholar
• Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994; 20: 1121–30
   PubMed Web of Science ®Google Scholar
• Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single‐strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995; 108: 789–95
   PubMed Web of Science ®Google Scholar
• Knodell R G, Ishak K G, Black W C, Chen T S, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1991; 1: 431–5
   Google Scholar
• Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545–50
   PubMed Web of Science ®Google Scholar
• Tanaka T, Tsukiyama‐Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347–53
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291–7
   PubMed Web of Science ®Google Scholar